All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Designation to RC88 in Platinum-Resistant Recurrent Ovarian Cancer

January 12th 2024

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

January 12th 2024

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Acalabrutinib Is Not Associated With Increased Hypertension Risk in CLL

January 11th 2024

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

January 11th 2024

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

January 11th 2024

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

Advice From Experts: Taking Care of Caregivers, Too

January 11th 2024

National Family Caregivers Month is observed every November to honor the contributions and sacrifices caregivers make to support their loved ones.

NMPA Accepts and Grants Priority Review to NDA for Sovleplenib in Primary Immune Thrombocytopenia

January 11th 2024

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

January 11th 2024

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

First-in-Class YAP/TEAD Inhibitor Demonstrates Early Efficacy Targeting Hippo Pathway

January 11th 2024

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

Life With “The Most Extraordinary Job”

January 11th 2024

Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.

FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia

January 10th 2024

The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.

Engineered Bone Marrow Shows Preclinical Potential in Osteosarcoma

January 10th 2024

R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.

Adagrasib Approved in Europe for Pretreated KRAS G12C+ Advanced NSCLC

January 10th 2024

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 10th 2024

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

January 10th 2024

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.

Alana Welm, PhD, Receives Award For Breast Cancer Research

January 10th 2024

Alana Welm, PhD, received the 2023 American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research.

Wakelee Addresses NSCLC Treatment Considerations From Every Angle

January 10th 2024

Heather Wakelee, MD, discusses the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Allegheny Health Network Oncology Experts Dive Into Updates Within the Gynecologic Oncology Space

January 10th 2024

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

NCCN Adds Nirogacestat to Guidelines for Patients With Soft Tissue Sarcoma

January 9th 2024

The NCCN has updated its guidelines for soft tissue sarcoma to include nirogacestat as a systemic therapy option for patients with desmoid tumors.